FDC Limited (FDC.NS)
- Previous Close
452.65 - Open
453.75 - Bid 457.10 x --
- Ask 456.90 x --
- Day's Range
449.15 - 460.00 - 52 Week Range
282.05 - 487.70 - Volume
53,249 - Avg. Volume
267,934 - Market Cap (intraday)
74.315B - Beta (5Y Monthly) 0.22
- PE Ratio (TTM)
25.72 - EPS (TTM)
17.74 - Earnings Date May 23, 2024 - May 27, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date Mar 19, 2020
- 1y Target Est
--
FDC Limited manufactures and markets pharmaceutical products in India and internationally. The company offers specialized formulations for various therapeutic segments, including anti-infective, gastrointestinal, ophthalmological, vitamins/minerals/dietary supplements, cardiac, anti-diabetes, respiratory, gynaecology, dermatology, analgesics, and others; and oral rehydration salts. It provides specialized formulations primarily under the Zifi, Ziglim Plus 2, Vitcofol, Pyrimon DF, Zocon, Zoxan, Zathrin, Zipod, Amodep-AT, Zefu, Cotaryl, and Mycoderm brand names. The company also offers anti-oxidants, balanced energy drinks, and vitamins and nutraceuticals under the Electral, Enerzal, Humyl, Mum Mum 1, Prosoyal, Simyl, and Zefrich brands. In addition, it provides various active pharmaceutical ingredients. The company was founded in 1936 and is headquartered in Mumbai, India.
www.fdcindia.com6,372
Full Time Employees
March 31
Fiscal Year Ends
Sector
Related News
Performance Overview: FDC.NS
Trailing total returns as of 4/25/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: FDC.NS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: FDC.NS
Valuation Measures
Market Cap
73.71B
Enterprise Value
70.11B
Trailing P/E
25.50
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
3.88
Price/Book (mrq)
3.74
Enterprise Value/Revenue
3.67
Enterprise Value/EBITDA
16.73
Financial Highlights
Profitability and Income Statement
Profit Margin
15.12%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
19.16B
Net Income Avi to Common (ttm)
2.9B
Diluted EPS (ttm)
17.74
Balance Sheet and Cash Flow
Total Cash (mrq)
3.83B
Total Debt/Equity (mrq)
1.25%
Levered Free Cash Flow (ttm)
--
Research Analysis: FDC.NS
Company Insights: FDC.NS
FDC.NS does not have Company Insights